A Laval firm developing drugs to fight diabetes and obesity entered the industry in a novel way, and its strategy is paying off. Unlike most pharmaceutical start-ups, Innodia Inc. wasn't rolled out of a university laboratory or split off a larger drug company. Claude Vezeau, the founder of the Laval-based biopharmaceutical company, took a different approach. First, he designed the company's shell. Then, he began to search for a product.